A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman

Wei-bin Zhou†, Nan Chen† and Cheng-jiang Li*

Abstract

Background: Hyperandrogenemia is more common in puberty and reproductive age, but relatively rare in postmenopausal women. Postmenopausal virilization may result from androgen-producing tumors. Androgen-secreting adrenal tumors are rare in clinical practice and are diagnosed as adrenocortical carcinoma, most of which can co-secrete androgen and cortisol. Highly elevated serum testosterone level with normal adrenal androgens such as dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS) and androstenedione is usually regarded as ovary origin. Here we describe an unusual case of a postmenopausal woman with markedly elevated serum testosterone level, while DHEAS, androstenedione, 17-hydroxyprogesterone and cortisol were within the normal range.

Case presentation: A 67-year-old postmenopausal woman with hirsutism in the upper lip and armpit, accompanied by clitoromegaly for 5 months. Hormonal evaluation showed markedly elevated serum testosterone level (714.8 ng/ml), whereas DHEAS, androstenedione, 17-hydroxyprogesterone, and cortisol were within the normal range. Imaging examination showed a mass of 1.5 cm in diameter in the left adrenal gland and normal appearance of both ovaries. PET-CT indicated that it was a case of benign adrenal adenoma and excluded ovarian abnormalities and other ectopic tumors. Thus, a pure testosterone-secreting adrenal tumor was suspected and then adrenalectomy was performed. Histology and immunohistochemistry furtherly confirmed the benign adrenocortical adenoma with immunohistochemistry positive for inhibin α, melan A, β-catenin, SYN (focal), Ki-67(< 3%), and negative for chromogranin (CgA), cytokeratin (CK), S-100, P53. After surgery, the level of testosterone returned to normal range and the clinical symptoms also subsided.

Conclusions: Pure testosterone-secreting adrenal adenomas are extremely rare, but it can induce severe hyperandrogenism and virilization. The source identification of hyperandrogenemia only based on the levels of testosterone, DHEAS and androstenedione is limited. It is important to evaluate not only ovaries but also adrenals in all women with virilization particularly during menopause, even their androstenedione, DHEA and DHEAS level are normal.

Keywords: Hyperandrogenism, Postmenopause, Adrenal tumors, Testosterone, Immunohistochemistry
Background
Hyperandrogenemia is more common in adolescence and childbearing age, but relatively rare in postmenopausal women. Due to the lack of clinical and epidemiological data of postmenopausal women with hyperandrogenemia, the clinical diagnosis and treatment are often difficult. A highly elevated testosterone level and manifestations of hyperandrogenism such as hirsutism and virilization in a postmenopausal woman strongly suggest the potential androgen-producing tumor [1]. Dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS) and androstenedione are mainly produced in the adrenal glands. The increased DHEAS was used as a marker of increased adrenal activity, so the circulating DHEAS level has been used to screen androgen from ovary or adrenal gland [2]. Functional adrenal tumors mainly include those secreting aldosterone or cortisol, and a few secreting both cortisol and androgen, but pure androgen-secreting adrenal tumors (PASATs) are rare, most of which are reported as case studies, and this kind of PASATs that only secrete testosterone with normal adrenal androgens (DHEA, DHEAS and androstenedione) are more rare [3].

Herein, we report a case of benign androgen-secreting adrenal tumor in a postmenopausal elderly woman, with markedly elevated testosterone levels while DHEAS and androstenedione were within normal range.

Case presentation
A 67-year-old postmenopausal woman with hirsutism of increased hair around the upper lip and armpit and clitoromegaly for five months was referred to the endocrinology clinic of our hospital. She had normal physiological development during her infancy and childhood, and also has a normal sexual life with no other medical history. Her menarche was at 18 years old, and her menopause at age of 56. She had a normal menstrual history before menopause and had no postmenopausal bleeding. She had two healthy children and no miscarriages. She denied taking estrogen, and had no postmenopausal bleeding. She had two healthy children and no miscarriages. She denied taking estrogen, and had no postmenopausal bleeding.

On physical examination, she was 153 cm tall and weighed 53 kg with body mass index of 22.6 kg/m². Increased hair was observed in her upper lip and armpit (Ferriman- Gallwey score of 8), and a physical examination of genital revealed clitoromegaly. There was no acne, deepening of the voice or other virilization signs. Findings on examination of the head and neck, breasts and abdomen were unremarkable. She had no signs of Cushing syndrome, or acanthosis nigricans syndrome.

The hormonal test showed high total testosterone levels (714.8 ng/dL, reference value 14–56). Serum DHEAS (145.8 ng/mL, reference value 25.9–460.2), androstenedione (2.4 ng/mL, reference value 0.3–3.3) and 17-hydroxyprogesterone (1.7 nmol/l, reference value 0–11.5) levels were within normal range. The serum values of follicle-stimulating hormone, luteinizing hormone, and prolactin were also within the normal range for the menopause. The levels of anti-mullerian hormone, human chorionic gonadotropin (hCG), thyroid-stimulating hormone (TSH), plasma renin activity and aldosterone, adrenocorticotropic hormone (ACTH), serum cortisol, 24-h urinary free cortisol, and 1 mg dexamethasone suppression test were in normal range. The ovarian tumor markers (Ca 125, CEA, Ca 199) were in normal reference range. The repeated samples confirmed that her high testosterone levels were within the tumor range. We excluded overt Cushing Syndrome on the basis of normal cortisol suppression after 1 mg dexamethasone and normal urinary free cortisol levels, as recently proposed by Ceccato F [4]. Then a middle dosage dexamethasone test (0.75 mg, 4 times a day for 5 consecutive days) without testosterone inhibition strongly suggested the potential androgen-producing tumor, further examinations were needed to distinguish ovarian or adrenal origin of hyperandrogenemia.

Initially, the lack of co-secretion of DHEAS and androstenedione indicated that her elevated testosterone might be of ovarian origin. However, pelvic ultrasound disclosed that there was no ovarian mass, while adrenal ultrasound showed a hypoechoic nodule in the left adrenal gland. Further pelvic magnetic resonance image (MRI) showed submucous myoma of uterus, but no abnormal of ovarian, and adrenal CT scan was also performed and a left adrenal mass of about 1.5 cm in diameter was revealed (Fig. 1 a and b). PET-CT confirmed a round nodule in the external branch of the left adrenal gland with slight increase in FDG metabolism (the SUV max of the nodule was 2.56), considering the possibility of benign adenoma. No ovarian abnormalities or other ectopic tumors were found by PET-CT.

Based on the clinical characteristics, hormone detection and imaging appearances of the case, pure testosterone-secreting adrenal tumor was suspected. Subsequently, the patient underwent a laparoscopic resection of left adrenal tumor. Histological examination (Fig. 2 a) and immunohistochemistry also confirmed the diagnosis of benign adrenocortical adenoma with immunohistochemistry positive for inhibin α, melan A, β-catenin (Fig. 2 b-d), SYN (focal), Ki-67 (< 3%), and negative for chromogranin (CgA), cytokeratin (CK), S-100, P53. The level of testosterone decreased to 15.8 ng/dl on the 3rd day after operation, and the symptoms of virilization were alleviated during the follow-up, which further confirms the adrenal etiology of the testosterone production.

Discussion and conclusions
The postmenopausal female with elevated androgens may present with symptoms of hirsutism and virilization.
Hirsutism is defined as excessive terminal hair that appears in a male pattern. Virilization includes balding, deepening of the voice, cystic acne and clitoromegaly. The main androgens in women are testosterone, dihydrotestosterone, DHEA, DHEAS and androstenedione. Among them, testosterone is the most active and also plays an important physiological role. One fourth of testosterone is synthetized in the adrenal gland, one fourth in the ovaries and a half produced from the peripheral conversion of their precursors (androstenedione, DHEAS, DHEA) [2]. The major androgens secreted by adrenal cortex are DHEA and its sulfate (DHEAS), and androstenedione while only a small amount of testosterone was directly synthesized by adrenal cortex [5]. Therefore, the increase of serum DHEA, DHEAS, androstenedione is generally regarded as adrenal origin, and isolated elevated testosterone is usually thought to originate from the ovary in women with hyperandrogenemia [6]. The main differential diagnosis of hyperandrogenemia is either tumoral causes, namely androgen-secreting ovarian or adrenal tumors, or non-tumoral causes, such as polycystic ovarian syndrome, Cushing’s syndrome, congenital adrenal hyperplasia, and iatrogenesis. The postmenopausal woman with rapid progression of clinical symptoms or highly elevated testosterone levels should be suspected of androgen-producing tumors [1, 7]. In postmenopausal woman, ovarian causes of hirsutism and virilization are more common than adrenal origin, while the adrenal etiology of androgen production was confirmed in our case. Androgen-secreting adrenal tumors, most of which co-secrete androgen and cortisol, are rare in clinical practice and often diagnosed as adrenocortical carcinoma, while pure androgen-secreting adrenal tumors (PASATs) are more rarely.

![Fig. 1 Adrenal CT (a) and enhanced CT (b) identified a left adrenal mass, 1.5 cm in diameter (Arrow). CT = computed tomography](image)

![Fig. 2 Hematoxylin and eosin staining of the adrenal tumor. Magnification x 100 (a); immunohistochemistry showing tumor tissue that stained positive for inhibin α (b), melan A (c), β-catenin (d)](image)
Moreno et al. [8] reviewed 801 adrenalectomies from 1970 to 2003, only 21 cases were due to PASATs, while all these PASATs had elevated testosterone and DHEAS.

It can be seen from above that PASATs are rare and usually accompanied by a concomitant increase in common adrenal androgens such as DHEA, DHEAS, and androstenedione. Our case is unusual, for that testosterone levels were within tumor range, while the serum DHEAS, androstenedione levels were normal. The imaging results, postoperative pathology and postoperative normal testosterone levels confirm the adrenal etiology of the androgen production. As to our knowledge, very few cases of PASATs that only secrete testosterone had been reported [9–12]. From these cases, we find that adrenal tumors secreting testosterone often have low malignant potential and misdiagnosed as ovarian disease due to its normal DHEAS levels. Surgical resection has a good effect on treatment of these tumors, but none of them did immunohistochemistry to confirm the nature of these tumors. In our case, immunohistochemistry showed that the tumor was positive for inhibin α, melan A, SYN (focal +), Ki-67 (< 3%), negative for CK, CgA, S-100, which supported benign adrenocortical adenoma.

The exact pathogenesis of these testosterone-secreting adrenal tumors is unclear. In healthy individuals, circulating DHEAS levels are known to reach a peak in the early 20s, and decrease linearly thereafter [13]. Carlos Morán et al. [14] found that such an age-related decrease of DHEAS levels also exists in hyperandrogenemia patients. Therefore, we speculate that DHEAS levels may tend to be not high in elder women with PASATs. Aguirre [15] suggested that testosterone-only adrenal tumors may actually originate from translocated gonadal cells. From 1981 to the present, to our knowledge, a total of 4 cases of adrenal adenoma secreting androgen were reported to have been found the specific Reinke crystallization of Leydig cells, suggesting the possibility of differentiation into Leydig cells during the process of tumorigenesis and development of tumor cells [11, 16–18]. In this case, we didn’t find Reinke crystallization. However, the absence of these inclusions does not exclude a Leydig cell character, because those inclusions are present in only 40% of Leydig cell tumors and the immunohistochemistry of our patient revealed that the tumor was positive for inhibin α. Inhibin α was a commonly used immunohistochemical index for diagnosis of Leydig’s cell tumor, even the specificity of inhibin α is limited since it is also expressed in adrenal cortical tumors. Besides, it was revealed that β-catenin over-expression might be also involved in the tumorigenesis of these pure testosterone-secreting adrenal adenomas.

When hirsutism accompanied by virilization signs such as severe balding and clitoromegaly appear in postmenopausal women, an underlying androgen-secreting tumor should be suspected. Adrenal tumors secreting only testosterone with no concomitant increase of common adrenal androgens such as DHEA, DHEAS, and androstenedione are extremely rare. This case reports an unusual case of a postmenopausal woman with a pure testosterone-secreting adrenal adenoma and shows that in the daily clinic, the source identification of hyperandrogenemia only based on the levels of testosterone, DHEAS and androstenedione is limited. The suspicious patients are recommended to receive a thorough pelvic examination and adrenal imaging examinations. The testosterone secreting tumors are able to induce severe hyperandrogenism and virilization, and laparoscopic resection provides a very effective treatment. PET-CT is helpful in differentiating benign or malignant testosterone-secreting adrenal tumors and excluding ectopic tumors.

In conclusion, our case indicates the importance to evaluate not only ovaries but also adrenals in all women with virilization particularly during menopause, even their androstenedione, DHEA and DHEAS level are normal.

**Abbreviations**

ACTH: Adrenocorticotropic hormone; CgA: Chromogranin; CK: Cytokeratin; DHEA: Dehydroepiandrosterone; DHEAS: Dehydroepiandrosterone sulfate; hCG: Human chorionic gonadotropin; MRI: Magnetic resonance image; PASATs: Pure androgen-secreting adrenal tumors; SUV: Standard uptake values; TSH: Thyroid-stimulating hormone

**Acknowledgements**

Research project of Zhejiang Provincial Education Department (Y201737212 to WZ), Zhejiang medical science and technology projects (2018KY056 to WZ).

**Funding**

No funding was required for the reporting of this work.

**Availability of data and materials**

The datasets supporting the conclusions of this article is included within the article and in figures.

**Authors’ contributions**

WZ and NC were involved in acquisition of data and drafting the manuscript. LJ is corresponding author and organized the study. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was carried out in accordance with the Helsinki Declaration and approved by the the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. Written informed consent was obtained from all participants.

**Consent for publication**

Written informed consent to publish has been obtained from the person described in this case report and study participants.

**Competing interests**

The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 15 November 2018 Accepted: 14 January 2019
Published online: 23 January 2019

References
1. Alpanes M, Gonzalez-Casbas JM, Sanchez J, Pian H, Escobar-Morreale HF. Management of postmenopausal virilization. J Clin Endocrinol Metab. 2012;97(8):2564–8.
2. Burger HG. Androgen production in women. Fertil Steril. 2002;77(Suppl 4):S3–S.
3. Rodriguez-Gutierrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J. Pure androgen-secreting adrenal adenoma associated with resistant hypertension. Case Rep Endocrinol. 2013;2013:356086.
4. Ceccato F, Antonelli G, Frigo AC, Regazzo D, Plebani M, Boscaro M, Scaroni C. First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. J Endocrinol Invest. 2017;40(7):753–60.
5. Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med. 1994;331(15):968–73.
6. Tutzer M, Winnykamien I, Davila Guardia J, Castelo-Branco C. Hyperandrogenism in post-menopausal women: a diagnosis challenge. Gynecol Endocrinol. 2014;30(1):23–5.
7. Glintborg D, Altinok ML, Petersen KR, Ravn P. Total testosterone levels are often more than three times elevated in patients with androgen-secreting tumours. BMC Case Rep. 2015;2015.
8. Moreno S, Montoya G, Armstrong J, Leteurtre E, Aubert S, Vantyghem MC, et al. Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases. Surgery. 2004;136(6):1192–8.
9. Leinonen P, Ranta T, Siegberg R, Pelkonen R, Kahri A. Testosterone-secreting virilizing adrenal adenoma with human chorionic gonadotrophin receptors and 21-hydroxylase deficiency. Clin Endocrinol. 1991;34(1):31–5.
10. Ruutiainen K, Satokari K, Anttila L, Erkkola R, Adrenal- and ovarian-vein steroids and LH response to GnRH in two patients with virilizing adrenocortical adenoma studied by selective catheterizations. Horm Res. 1992;37(1–2):49–53.
11. Ryan J, Rezkalla M, Rizk S, Peterson K, Wiebe R. Testosterone-secreting adrenal adenoma that contained crystalloids of Reinke in an adult female patient. Mayo Clin Proc. 1995;70(4):380–3.
12. Daniłowicz K, Allibger N, Vanegas M, Gomez RM, Cross G, Bruno OD. Androgen-secreting adrenal adenomas. Obstet Gynecol. 2002;100(S Pt 2):1099–102.
13. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59(3):551–5.
14. Moran C, Knochenhauer E, Boots LR, Aziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril. 1999;71(4):671–4.
15. Aguirre P, Scully RE. Testosterone-secreting adrenal ganglioneuroma containing Leydig cells. Am J Surg Pathol. 1983;7(7):699–705.
16. Trost BN, Koenig MP, Zimmermann A, Zachmann M, Muller J. Virilization of a post-menopausal woman by a testosterone-secreting Leydig cell type adrenal adenoma. Acta Endocrinol (Copenh). 1981;98(2):274–82.
17. Vasloff J, Chideckel EW, Boyd CB, Foshag LJ. Testosterone-secreting adrenal adenoma containing crystalloids characteristic of Leydig cells. Am J Med. 1985;79(6):772–6.
18. Pollock WJ, McConnell CF, Hilton C, Lavine LR. Virilizing Leydig cell adenoma of adrenal gland. Am J Surg Pathol. 1986;10(11):816–22.